FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197841346> ?p ?o ?g. }

• W3197841346 abstract "Background Mounting randomized clinical trials have proved that immune checkpoint inhibitors (ICIs) achieved better overall survival (OS) and progression-free survival (PFS) than chemotherapy drugs for advanced non-small cell lung cancer (NSCLC) patients. However, some literatures have indicated that different sexes might not have equal immune response. Also, no agreement reached on the issue whether therapeutic benefit of ICIs is related to sex. Objectives To explore the association between efficacy of ICIs for NSCLC patients and their sexes and summarize overall treatment-related adverse events (TRAEs) in an exploratory manner. Methods We performed this systematic review and meta-analysis of all potentially relevant studies retrieved from PubMed, EMBASE, and the Cochrane Library until June 2021, for eligible randomized controlled trials (RCTs) comparing immunotherapy with chemotherapy in advanced NSCLC patients. Literature screening, summary data extraction was performed independently and in duplicate. The pooled hazard ratio (HR) and 95% confidence interval (CI) of OS, PFS and TRAEs were calculated, applying STATA software and random-effects models. This study was registered in international prospective register of systematic reviews (PROSPERO), number CRD42020210797. Results Twenty-one trials involving 12,675 NSCLC patients were included. For patients with advanced NSCLC, ICIs significantly prolonged the OS (males: HR 0.73, 95%CI 0.67-0.79; females: HR 0.73, 95%CI 0.61-0.85) and PFS (males: HR 0.62, 95%CI 0.55-0.70; females: HR 0.68, 95%CI 0.55-0.81) versus chemotherapy. Overall, there was no statistical difference between their sexes (OS: P = 0.97; PFS: P = 0.43), respectively. Owing to insufficient TRAEs data of different sexes, we only found immunotherapy for NSCLC patients had more all-grades (RR 0.88; 95%CI 0.82-0.95) and 3-5 grades (RR 0.60; 95%CI 0.47-0.75) AEs compared with chemotherapy. Conclusion Our findings indicated that the interaction between immunotherapy efficacy and different sexes was equally evident. Overall, patients with NSCLC could obtain more benefits from ICIs than chemotherapy regimen regardless of their sexes. Systematic Review Registration PROSPERO ( https://www.crd.york.ac.uk/prospero/ ), identifier CRD42020210797." @default.
• W3197841346 created "2021-09-13" @default.
• W3197841346 creator A5024548083 @default.
• W3197841346 creator A5048686196 @default.
• W3197841346 creator A5057981587 @default.
• W3197841346 creator A5063408281 @default.
• W3197841346 creator A5064771705 @default.
• W3197841346 creator A5073568638 @default.
• W3197841346 creator A5079183348 @default.
• W3197841346 creator A5088482310 @default.
• W3197841346 date "2021-08-26" @default.
• W3197841346 modified "2023-10-11" @default.
• W3197841346 title "Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients" @default.
• W3197841346 cites W1600041372 @default.
• W3197841346 cites W1923772614 @default.
• W3197841346 cites W2030411079 @default.
• W3197841346 cites W2054841768 @default.
• W3197841346 cites W2060070314 @default.
• W3197841346 cites W2098923148 @default.
• W3197841346 cites W2104347254 @default.
• W3197841346 cites W2125435699 @default.
• W3197841346 cites W2156098321 @default.
• W3197841346 cites W2156353875 @default.
• W3197841346 cites W2280957887 @default.
• W3197841346 cites W246286872 @default.
• W3197841346 cites W2527905628 @default.
• W3197841346 cites W2567564314 @default.
• W3197841346 cites W2572174216 @default.
• W3197841346 cites W2588336706 @default.
• W3197841346 cites W2588681363 @default.
• W3197841346 cites W2591772299 @default.
• W3197841346 cites W2635951006 @default.
• W3197841346 cites W2753529762 @default.
• W3197841346 cites W2784371446 @default.
• W3197841346 cites W2796582438 @default.
• W3197841346 cites W2886586335 @default.
• W3197841346 cites W2889646458 @default.
• W3197841346 cites W2892310829 @default.
• W3197841346 cites W2892640821 @default.
• W3197841346 cites W2894926481 @default.
• W3197841346 cites W2895926103 @default.
• W3197841346 cites W2907028960 @default.
• W3197841346 cites W2910245285 @default.
• W3197841346 cites W2925446385 @default.
• W3197841346 cites W2946386783 @default.
• W3197841346 cites W2948936033 @default.
• W3197841346 cites W2950627686 @default.
• W3197841346 cites W2966340800 @default.
• W3197841346 cites W2966485342 @default.
• W3197841346 cites W2976744492 @default.
• W3197841346 cites W2989313910 @default.
• W3197841346 cites W3017322331 @default.
• W3197841346 cites W3035845224 @default.
• W3197841346 cites W3045379462 @default.
• W3197841346 cites W3047859155 @default.
• W3197841346 cites W3064958262 @default.
• W3197841346 cites W3088573921 @default.
• W3197841346 cites W3091399767 @default.
• W3197841346 cites W3097223462 @default.
• W3197841346 cites W3107870684 @default.
• W3197841346 cites W3110814768 @default.
• W3197841346 cites W3121907365 @default.
• W3197841346 cites W3129022890 @default.
• W3197841346 cites W3144903047 @default.
• W3197841346 cites W3155244800 @default.
• W3197841346 cites W3165293110 @default.
• W3197841346 cites W4294215472 @default.
• W3197841346 doi "https://doi.org/10.3389/fonc.2021.627016" @default.
• W3197841346 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8427763" @default.
• W3197841346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34513654" @default.
• W3197841346 hasPublicationYear "2021" @default.
• W3197841346 type Work @default.
• W3197841346 sameAs 3197841346 @default.
• W3197841346 citedByCount "4" @default.
• W3197841346 countsByYear W31978413462022 @default.
• W3197841346 countsByYear W31978413462023 @default.
• W3197841346 crossrefType "journal-article" @default.
• W3197841346 hasAuthorship W3197841346A5024548083 @default.
• W3197841346 hasAuthorship W3197841346A5048686196 @default.
• W3197841346 hasAuthorship W3197841346A5057981587 @default.
• W3197841346 hasAuthorship W3197841346A5063408281 @default.
• W3197841346 hasAuthorship W3197841346A5064771705 @default.
• W3197841346 hasAuthorship W3197841346A5073568638 @default.
• W3197841346 hasAuthorship W3197841346A5079183348 @default.
• W3197841346 hasAuthorship W3197841346A5088482310 @default.
• W3197841346 hasBestOaLocation W31978413461 @default.
• W3197841346 hasConcept C126322002 @default.
• W3197841346 hasConcept C143998085 @default.
• W3197841346 hasConcept C168563851 @default.
• W3197841346 hasConcept C197934379 @default.
• W3197841346 hasConcept C207103383 @default.
• W3197841346 hasConcept C2776256026 @default.
• W3197841346 hasConcept C2776478404 @default.
• W3197841346 hasConcept C2776694085 @default.
• W3197841346 hasConcept C44249647 @default.
• W3197841346 hasConcept C535046627 @default.
• W3197841346 hasConcept C71924100 @default.
• W3197841346 hasConcept C95190672 @default.
• W3197841346 hasConceptScore W3197841346C126322002 @default.
• W3197841346 hasConceptScore W3197841346C143998085 @default.

• next